Genomic testing has become an essential part for diagnosis, prognosis, and treatment of many cancers, especially non-small cell lung cancer (NSCLC). Lung cancers account for ~ 13% of all new cancer diagnoses but make up almost 25% of all cancer deaths. The advances in molecular findings lead to the development of targeted therapies which have greatly improved patient management.
Predictive biomarkers testing in NSCLC include driver mutations in EGFR, KRAS, BRAF (p.V600E); fusions of the ALK, ROS1, NTRK1-3, and RET genes; MET exon 14 skipping, and PD-L1 expression by immunohistochemistry .
This Research Topic invites contributions of original research which address the following, but not limited to, the following areas of interest:
- New molecular tests/techniques for detecting of genomic aberrations in lung cancer
- Novel or repurposed treatments utilizable in NSCLC regarding biomarkers identified through molecular genetic testing
- Utilization of molecular testing in clinical practice such morphologic correlation and pathologic diagnosis.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Genomic testing has become an essential part for diagnosis, prognosis, and treatment of many cancers, especially non-small cell lung cancer (NSCLC). Lung cancers account for ~ 13% of all new cancer diagnoses but make up almost 25% of all cancer deaths. The advances in molecular findings lead to the development of targeted therapies which have greatly improved patient management.
Predictive biomarkers testing in NSCLC include driver mutations in EGFR, KRAS, BRAF (p.V600E); fusions of the ALK, ROS1, NTRK1-3, and RET genes; MET exon 14 skipping, and PD-L1 expression by immunohistochemistry .
This Research Topic invites contributions of original research which address the following, but not limited to, the following areas of interest:
- New molecular tests/techniques for detecting of genomic aberrations in lung cancer
- Novel or repurposed treatments utilizable in NSCLC regarding biomarkers identified through molecular genetic testing
- Utilization of molecular testing in clinical practice such morphologic correlation and pathologic diagnosis.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
